All Outputs (2)

Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes (2024)
Journal Article
Raniga, K., Nasir, A., Vo, N. T., Vaidyanathan, R., Dickerson, S., Hilcove, S., Mosqueira, D., Mirams, G. R., Clements, P., Hicks, R., Pointon, A., Stebbeds, W., Francis, J., & Denning, C. (2024). Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell, 31(3), 292-311. https://doi.org/10.1016/j.stem.2024.01.007

Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the... Read More about Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes.

Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes (2024)
Journal Article
Johnson, B. B., Cosson, M.-V., Tsansizi, L. I., Holmes, T. L., Gilmore, T., Hampton, K., …Smith, J. G. W. (2024). Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes. Cell Reports, 43(1), Article 113668. https://doi.org/10.1016/j.celrep.2023.113668

Perlecan (HSPG2), a heparan sulfate proteoglycan similar to agrin, is key for extracellular matrix (ECM) maturation and stabilization. Although crucial for cardiac development, its role remains elusive. We show that perlecan expression increases as c... Read More about Perlecan (HSPG2) promotes structural, contractile, and metabolic development of human cardiomyocytes.